CClinicalTrials.gg
Status unknownNCT05643989PATENCYUpdated Dec 9, 2022

Self-expandable Metal Stent (SEMS) Endoscopic Placement for Malignant Colonic Obstruction Therapy

An interventional study of Stoma formation and Endoscopic self-expandable metal stent placement in Neoplasms,Colorectal, sponsored by Russian Society of Colorectal Surgeons. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by Russian Society of Colorectal Surgeons · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Nov 2019, registered Jun 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Compare the effectiveness of Self-expandable metal stent (SEMS) and diverting stoma formation for the bowel preparation as a bridge to surgical treatment of patients with MCO.

Read the detailed description

Surgical treatment of MCO is associated with high mortality and frequent development of postoperative complications. Stoma formation is the traditional method of urgent treatment of MCO. Currently there are more than 150 methods of colorectal stomas formation, but all of themare associated with a high risk of complications (10-20%), inclusively both early and late postoperative period. It results in longerhospital stay and requires additional financial expenses, also reoperations can be fatal for patients.

Analysis of recent publications devoted to the treatment of MCO shows increasing implemented of new strategies of patents management, such as "fast track surgery", or "fast track recovery strategy" in clinical practice. Minimally invasive endoscopic procedures as a first stage of MCO treatment leads to transformation of previously performed multi-stage surgical interventions into one - stage.

Development of up-to-date endoscopic science and technology provides a wide usage ofself-expandable metal stent (SEMS) in clinical practice. This strategy helps to avoid stoma formation or emergency surgery, becoming a "bridge" to a radical surgery.

There are currently no studies directly comparing discharge stoma with endoscopic self-expandable metal stenting in preparation for colorectal cancer radical surgery.

02

Conditions studied

  • Neoplasms,Colorectal
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 56 is below the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Russian Society of Colorectal Surgeons is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients are 18 years old or older
  2. Stage I-IV according to TNM classification
  3. Patients with malignant colonic obstruction
  4. Overall health status according to ASA classification: I-III
  5. Overall health status according to Charlson comorbidity index ≤ 8 points
  6. Signed informed consent with agreement to attend all study visits
  7. The patient is not pregnant

Exclusion criteria

Exclusion Criteria:

  1. Inflammatory bowel disease
  2. Acute purulent process in the abdominal cavity
  3. The patient wants to withdraw from the clinical trial
  4. Loss to follow-up
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
56 participants (estimated)

Study arms

  • Active comparator
    Self-expandable metal stent (SEMS) endoscopic placement.

    Anesthesia will include only propofol injection. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis.

    Procedure: Endoscopic self-expandable metal stent placement

  • Placebo comparator
    Stoma formation.

    Anesthetic care will include general endotracheal anesthesia with positioning of nasogastric tube and bladder catheterization. The diverting stoma formation will be proceed in 10 sm proximally to tumor.

    Procedure: Stoma formation

Interventions

  • ProcedureStoma formation

    Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.

  • ProcedureEndoscopic self-expandable metal stent placement

    The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.

06

What researchers measure

Primary outcomes

  1. Bowel preparation (absence of feaces) according to Boston Bowel Preparation Scale

    Evaluated via colonoscopy in colon and rectum distal to the tumour. Total score of bowel preparation measured from 0 to 9. The maximum BBPS score for a perfectly clean colon without any residual liquid is 9 and the minimum BBPS score for an unprepared colon is 0. This is evaluated by the endoscopist

    Time frame: on the 3rd day after obstruction treatment (SEMS or stoma formation)

Secondary outcomes

  1. Intraoperative complications rate during stoma formation or stent placement

    The rate of complications during the procedure

    Time frame: 1 day (the day of procedure)

  2. Early postoperative complications rate after stoma formation or stent placement

    The rate of complications after the procedure

    Time frame: up to 7 days after procedure

  3. Length of hospital stay after stoma formation or stent placement

    Number of days spent in hospital after procedure

    Time frame: 30 days after procedure

  4. Quality of life before and after stoma formation or stent placement

    Measured by patient-reported SF-36 scale before and after procedure

    Time frame: -1 day (before procedure), 3rd and 7th day after procedure

  5. Operation time of resectional surgery

    The duration of surgical procedure in minutes

    Time frame: 1 day (the day of tumor resection surgery )

  6. Stoma formation rate

    The percentage of patients who had preventive or definitive stoma during resectional surgery in the SEMS group

    Time frame: 1 day (the day of tumor resection surgery )

  7. Stoma reversal rate

    The rate of previously formed stoma reversal simultaneously with tumor resection

    Time frame: 1 day (the day of tumor resection surgery )

  8. Early postoperative complications rate after resectional surgery

    The rate complications after tumor resection surgery

    Time frame: 30 days after resectional surgery

  9. Length of hospital stay after resectional surgery

    Number of days spent in hospital after tumor resection surgery

    Time frame: 30 days after resectional surgery

  10. Intraoperative complications rate during resectional surgery

    The rate of complications during tumor resection surgery

    Time frame: 1 day (the day of resectional surgery)

  11. Late complications rate during resectional surgery

    The rate of complications after tumor resection surgery

    Time frame: 31-90 days after tumor resection surgery

07

Study locations

1 of 1 sites recruiting
  • Clinic of colorectal and minimally invasive surgery University Hospital n2, Clinical Center Sechenov First Moscow State Medical University
    Moscow, Russian Federation
    Recruiting
08

References and documents

Publications

  • Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, Kohler BA, Jemal A. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018 Jul 1;124(13):2785-2800. doi: 10.1002/cncr.31551. Epub 2018 May 22. PubMed 29786848 ↗
  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum In: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. PubMed 21296855 ↗
  • Cheynel N, Cortet M, Lepage C, Benoit L, Faivre J, Bouvier AM. Trends in frequency and management of obstructing colorectal cancers in a well-defined population. Dis Colon Rectum. 2007 Oct;50(10):1568-75. doi: 10.1007/s10350-007-9007-4. PubMed 17687610 ↗
  • Baron TH. Colonic stenting: a palliative measure only or a bridge to surgery? Endoscopy. 2010 Feb;42(2):163-8. doi: 10.1055/s-0029-1243881. Epub 2010 Feb 5. PubMed 20140833 ↗
  • Larkin JO, Moriarity AR, Cooke F, McCormick PH, Mehigan BJ. Self-expanding metal stent insertion by colorectal surgeons in the management of obstructing colorectal cancers: a 6-year experience. Tech Coloproctol. 2014 May;18(5):453-8. doi: 10.1007/s10151-013-1073-0. Epub 2013 Oct 10. PubMed 24114608 ↗
  • Kim EJ, Kim YJ. Stents for colorectal obstruction: Past, present, and future. World J Gastroenterol. 2016 Jan 14;22(2):842-52. doi: 10.3748/wjg.v22.i2.842. PubMed 26811630 ↗
  • Maleckis K, Anttila E, Aylward P, Poulson W, Desyatova A, MacTaggart J, Kamenskiy A. Nitinol Stents in the Femoropopliteal Artery: A Mechanical Perspective on Material, Design, and Performance. Ann Biomed Eng. 2018 May;46(5):684-704. doi: 10.1007/s10439-018-1990-1. Epub 2018 Feb 22. PubMed 29470746 ↗
  • Nakata K, Fukunaga M, Ebihara T, Kato F, Amano K, Babaya A, Matsushita A, Furukawa H, Matsushima Y, Matsumoto H, Fujihara S, Kawabata R, Usui A, Yamamoto T, Oda K, Kawase T, Kimura Y, Nakata Y, Ohzato H. [A study of laparoscopic stoma creation for patients with malignant bowel obstruction]. Gan To Kagaku Ryoho. 2013 Nov;40(12):1702-4. Japanese. PubMed 24393894 ↗
  • van den Berg MW, Ledeboer M, Dijkgraaf MG, Fockens P, ter Borg F, van Hooft JE. Long-term results of palliative stent placement for acute malignant colonic obstruction. Surg Endosc. 2015 Jun;29(6):1580-5. doi: 10.1007/s00464-014-3845-7. Epub 2014 Oct 8. PubMed 25294532 ↗
  • Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol. 2013 Apr;29(2):44-54. doi: 10.3393/ac.2013.29.2.44. Epub 2013 Apr 30. PubMed 23700570 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05643989
Lead sponsor
Russian Society of Colorectal Surgeons
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Nov 1, 2019
Primary completion
Feb 1, 2023 (estimated)
Completion
May 11, 2023 (estimated)
Last update
Dec 9, 2022

Study contacts

Irina Gorovaia, MD
Contact
rudenko@kkmx.com
+79175998459
Inna Tulina, MD
Contact
tulina@kkmx.ru
+79264086672
Petr Tsarkov, Prof
principal investigator · Russian Society of Colorectal Surgeons

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion